Skip to main content
Menu
HTRF TAZ- deficiency barth syndrome
Literature - Publication Review

Impact of taz deficiency on mitochondrial metabolism and pancreatic islet compensation in barth syndrome

A new study investigates how pancreatic islet function is preserved in Barth syndrome, a rare genetic disorder that disrupts mitochondrial metabolism. Leveraging Revvity's HTRF™ assay technology, the researchers uncovered unexpected compensatory mechanisms at the cellular and systemic level.

Key Findings:

  • Preserved insulin secretion despite Taz-related mitochondrial dysfunction
  • Increased glucagon secretion as an adaptive α-cell response
  • FGF-21 signaling rescued β-cell function in vitro

Read the full publication review to learn how HTRF supported these insights.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
Image CAPTCHA
Get new captcha!

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Download Resource

Impact of taz deficiency on mitochondrial metabolism and pancreatic islet compensation in barth syndrome

Download Literature - Publication Review

Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.

Revvity AI Assistant Beta

Scroll Icon